Aura Biosciences jumps as dosing begins in cancer drug study

Aura Biosciences

28/09/2022 17:34

** Shares of Aura Biosciences Inc  AURA.O  rise ~21% to
$18.64 - set for their best day since last year's debut, if
gains hold
    ** Co says first patient has been dosed in an early-stage
study testing its drug candidate, belzupacap sarotalocan, for
treating a type of bladder cancer  urn:newsml:reuters.com:*:nBw7VvNRka
    ** AURA expects to enroll nearly 23 adult patients with the
disease and plans to report data from the trial in 2023
    ** Drug already has a "fast track" tag from U.S. FDA
    ** Including session's gain, stock up ~10% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))